Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 - Symptomatic treatment - Document - PDFSEARCH.IO

First Page	Meta Content
	Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 Add to Reading List Document Date: 2015-01-27 15:09:34 Open Document File Size: 50,94 KB Share Result on Facebook City Osaka / London / / Company Shionogi Inc. / Shionogi & Co / Shionogi Limited. / Shionogi & Co. Ltd. / Corporate Communications Department Shionogi & Co. Ltd. / / Continent Europe / / Country United Kingdom / Japan / United States / / / IndustryTerm pharmaceutical / foreign healthcare reforms / with respect to product / / MedicalCondition dyspareunia / obesity / infectious diseases / pain/CNS disorders / metabolic disease / / / URL www.shionogi.co.jp/en / www.ema.europa.eu/ema / www.shionogi.com / www.shionogi.eu / / SocialTag Shionogi Menopause Dyspareunia Estrogen Vaginal lubrication Human reproduction Endocrine system Reproductive system

Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1Add to Reading List